NOT-CA-21-001: Notice of Extension of the Expiration Date of PAR-19-363 "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)"

Notice of Extension of the Expiration Date of PAR-19-363 "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)"

Notice Number:

NOT-CA-21-001

Key Dates

Release Date:

October 5, 2020

Related Announcements

PAR-19-363 - Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to extend the expiration date of PAR-19-363 "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)" by one Standard Application Due Date.

Therefore, with the addition/extension by one Standard Application Due Date of June 5, 2021 (new applications), July 5, 2021 (resubmission applications), and the Standard AIDS date (September 7, 2021), PAR-19-363 will now expire on September 8, 2021.

The following section of the FOA has been changed:

Part 1. Overview Information, Key Dates

Currently reads:

Expiration Date

May 08, 2021

Corrected to read (in italics):

Expiration Date

September 8, 2021

All other aspects of PAR-19-363 remain unchanged.

Inquiries

Please direct all inquiries to:

Chiayeng Wang, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6624
Email: [email protected]